NKN. Yu. Koroleva

N. Yu. Koroleva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. Yu. Koroleva has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Close Relationship Between Apnea, Epilepsy and SUDEP

    by N.Y. Koroleva, A.V. Markin

    A review of recent publications about sleep apnea and epilepsy has been shown that the respiratory system plays a crucial role in the development of sudden unexpected death in epilepsy (SUDEP). Sleep apnea can provoke or worsen epilepsy, and treatment of sleep apnea can reduce the number of seizures. The International Antiepileptic League identifies a special group of sleep-related epilepsies (sleep-accentuated epilepsies; sleep-associated epilepsies; epilepsy of awakening), among which, first of all, apnea screening should be carried out. In patients with apnea and epilepsy, the use of medications and therapies that cause or exacerbate apnea attacks should be limited. Apnea therapy should be used in a comprehensive and individualized way, in particular, treatment of obesity, CPAP therapy, sultiam (from 200 mg/day for adult patients with apnea and epilepsy), treatment of ENT pathology, etc. are recommended.


  • Open Access

    Structural epilepsy in a patient with multiple sclerosis

    by N. V. Muzhikina, N. Y. Koroleva, G. V. Kataeva, A. D. Korotkov, I. D. Stolyarov

    Clinical case of structural epilepsy in a patient with multiple sclerosis is presented, which shows the achievement of seizure’s stable remission, which is extremely rare in forms of epilepsy with a multi-focal lesion another etiology and a long history of the disease without combination with multiple sclerosis. Video-EEG monitoring, positron emission tomography of the brain with 18F-deoxyglucose, expand the possibilities of diagnosing form of epilepsy in patients with combined pathology, which allows prescribing adequate therapy.


  • Open Access

    Clinical case of a patient with focal cortical dysplasia IIa adjacent to the speech center: diagnostic and therapeutic algorithms

    by N. V. Muzhikina, N. Yu. Koroleva, V. R. Kasumov, P. V. Pushnoy, A. D. Korotkov, I. A. Kotomin, M. V. Kireev

    A clinical case of a patient with pharmacoresistant epilepsy due to focal cortical dysplasia (PCD) directly adjacent to the speech zone in the left temporal region is presented. The diagnostic search and transition from MRI-negative form to structural focal epilepsy progressed for more than 6 years. It was accounted for by the fact that type IIa vs. IIb FCD is visualized much worse, magnetic resonance imaging (MRI) signs of type IIa FCD are not so prominent, so that this type of dysplasia is often omitted. Functional research methods in epileptology, such as video-electroencephalography monitoring, brain positron emission tomography with 18F-fluorodeoxyglucose, functional MRI of speech zones, allow to more accurately verify the form of epilepsy and determine a scope of surgical treatment. Surgical intervention in carefully selected patients may contribute to favorable outcome of epilepsy (Engel 1, 51-months follow-up), which will lead to improved quality of life.


  • Open Access

    Efficacy and safety of using vagus nerve stimulation in patients with pharmacoresistant epilepsy in the Russian Federation: a multi-center retrospective observational program

    by K. V. Voronkova, M. N. Klochkov, N. Yu. Koroleva, S. S. Ivanov, A. B. Dmitriev, E. S. Bolshakova, E. F. Fatykhova, A. A. Usoltseva, D. V. Dmitrenko, A. A. Feygina, et al.

    Objective: to assess efficacy and safety of vagus nerve stimulation (VNS) in patients with pharmacoresistant epilepsy.Material and methods. A multi-center retrospective observational program was applied in patients with pharmacoresistant epilepsy by using vagus nerve stimulation for at least 2 years. There were enrolled 151 subjects, patient age on stimulator implantation varied from 5 to 65 years (24.4±13.1 years). Among them, subjects under 18 or at least 18 years of age comprised 58 (38.4%) and 93 (61.6%), respectively. Changes in rate and severity of major group epileptic seizures (highly disabling type) 24 months after VNS-therapy vs. baseline state as well as during 3-, 6-, 9-, 12-month follow-up were compared. There were assessed stimulator-related effects on VNS-therapy as well as patient quality of life 2 years after therapy. The dynamics of the frequency of all types of epileptic seizures was evaluated according to McHugh Outcome scale.Results. Mean epilepsy duration on stimulator implantation was 170.9±126.8 months, with maximum up to 666 months (55 years). Number of patients with dominant (disabling) seizures on implantation procedure comprised 136 (90.1%). Decline in dominant epileptic seizure rate by 50–99% was recorded in 91 patients (66.9%) 24 months after VNStherapy. Among such subjects were 41 patients (30.15%) featured with disabling seizures including 24 fully seizure free subjects (17.65%). Decreased rate of all group epileptic seizures by more than 50% (responders) was found in 52.9% cases, including subjects under 18 and adults in 63.9% and as few as 46.3% (pConclusion. Vagus nerve stimulation is an effective and safe auxiliary treatment method for therapy of pharmacoresistant epilepsy both in children and adults.